DUET-01 Trial Insights at ASCO 2024

SOTIO Biotech, a clinical-stage immuno-oncology firm under the PPF Group, has announced its participation in the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will showcase a poster detailing the progress of its Phase 1/2 DUET-01 study, which is focused on the innovative CAR T-cell therapy, BOXR1030. This therapy is designed to target GPC3, a protein commonly found in solid tumors, and has been enhanced with a gene that codes for GOT2, an enzyme pivotal for cellular metabolism.

The DUET-01 study is a pioneering human trial that will evaluate the safety and efficacy of BOXR1030 in a dose-escalation format. It aims to establish the optimal dosage for Phase 2 trials and will include approximately 98 participants suffering from advanced solid tumors that are GPC3 positive. The conditions targeted in this trial include hepatocellular carcinoma, squamous cell lung cancer, myxoid/round cell liposarcoma, and Merkel cell carcinoma.

The poster, titled "DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors," will be presented during the Developmental Therapeutics — Immunotherapy session on June 1, 2024. The session will run from 9:00 a.m. to 12:00 p.m. CDT, and the materials will be made available post-presentation.

SOTIO Biotech is at the forefront of cancer immunotherapy, committed to transforming scientific discoveries into tangible benefits for patients. The company's pipeline is robust, featuring SOT102, an antibody-drug conjugate targeting Claudin-18.2, which entered clinical trials in 2022. In addition to BOXR1030, SOTIO is developing other promising therapies such as SOT201, a next-generation PD-1 inhibitor.

SOTIO Biotech is a proud member of the PPF Group, a global private investment group with diverse interests.The company's dedication to advancing cancer treatments is evident through its ongoing research and development efforts, as showcased by its participation in prestigious conferences such as ASCO.